Idrabiotaparinux sodium

Drug Profile

Idrabiotaparinux sodium

Alternative Names: Biotinylated idraparinux; SSR 126517; SSR126517E

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Anticoagulants; Antithrombotics; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Discontinued Deep vein thrombosis; Embolism

Most Recent Events

  • 11 Dec 2008 Efficacy data from the phase III EQUINOX trial in Deep vein thrombosis presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008) (ADNM)
  • 03 Sep 2008 Pharmacodynamics data from a clinical trial in Thrombosis presented at the Congress of the European Society of Cardiology (ESC-2008)
  • 30 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top